U.S. markets closed

Ortho Regenerative Technologies Inc. (ORTIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.5703-0.0227 (-3.83%)
At close: 3:05PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5930
Open0.7800
BidN/A x N/A
AskN/A x N/A
Day's Range0.5200 - 0.7800
52 Week Range0.5200 - 0.7800
Volume30,418
Avg. VolumeN/A
Market Cap18.262M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ORTH.CN: OrthoRTI & Hanuman Partner on Buoy-Based PRP Prep
      Zacks Small Cap Research

      ORTH.CN: OrthoRTI & Hanuman Partner on Buoy-Based PRP Prep

      By John Vandermosten, CFA CNSX:ORTH.CN | OTC:ORTIF READ THE FULL ORTH.CN RESEARCH REPORT Ortho Regenerative Technologies (CNSX:ORTH) (OTC:ORTIF) announced on January 5, 2021 it had entered into an agreement with Hanuman Pelican, Inc. providing Ortho global rights (excluding Japan) to commercialize Hanuman’s Buoy Suspension Fractional System as a part of a turnkey offering for Ortho-R. The deal

    • Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc.
      PR Newswire

      Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc.

      Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) ("Ortho RTI" or the "Company"), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that it has entered into a global licensing agreement (the "Agreement") with Hanuman Pelican Inc. ("Hanuman") for the use of the Buoy Suspension Fractional System in combination with Ortho-R, Ortho RTI's lead Chitosan-PRP hybrid drug/biologic implant combination product.

    • ORTH.CN: Meniscus Plan In Place
      Zacks Small Cap Research

      ORTH.CN: Meniscus Plan In Place

      By John Vandermosten, CFA CNSX:ORTH.CN | OTC:ORTIF READ THE FULL ORTH.CN RESEARCH REPORT Third Quarter Fiscal Year 2021 Operational and Financial Results Ortho Regenerative Technologies Inc. (CNSX:ORTH.CN) (OTC:ORTIF) reported third quarter fiscal year 2021 financial and operational results and submitted its SEDAR filings on December 18, 2020. During 3Q:21, extending from August 1 to